Scancell Holdings plc (Scancell) is a biopharmaceutical company, engaged in developing novel therapeutic cancer vaccines for the treatment of cancer and infectious diseases. The company through its subsidiary Scancell Limited principally focuses on the cancer therapeutics market. Currently, it is developing a pipeline of cancer and infectious diseases vaccines based on its ImmunoBody platform. Its products in development includes cancer vaccine (SCIB1), a plasmid DNA under pre-clinical development for the treatment of melanoma; and ImmunoBody (SCIB2) is an anti-angiogenic vaccine that is expected to have utility in the treatment of any solid tumour. SCIB2 is used either as monotherapy or in combination with tumour specific vaccines, including SCIB1. Scancell is headquartered in Nottingham, the United Kingdom.